fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2010-02-18
Biotech partner: Swedish Orphan Biovitrum (Sweden)
Pharma Partner: BiogenIdec (USA)
Type of agreement: * R&D
* licensing
* commercialization/ distribution
* development
* marketing/ promotion
* other
Compound: recombinant Factor VIII Fc fusion protein (rFVIIIFc) recombinant Factor IX Fc fusion protein (rFIXFc)
Disease area: Hemophilia A and B
Development phase: rFVIIIFc is currently being evaluated in a Phase I/IIa open-label study. (See clinical_studies) rFIXFc has just entered registrational trials. (See clinical_studies)
Nature of the agreement: Biogen Idec and Swedish Orphan Biovitrum have restructured the collaboration agreement for the companies' long-acting, recombinant Factor VIII Fc fusion protein (rFVIIIFc) in hemophilia A patients and the recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B patients.

Under the amended agreement, Biogen Idec will assume full development responsibilities and costs, as well as manufacturing rights for the rFVIIIFc and rFIXFc programs. Biogen Idec also gains marketing responsibility for the rest-of-world territories that had previously been shared between the two companies, in addition to its existing commercial rights in North America. Swedish Orphan Biovitrum will retain commercial rights in Europe, Russia, Turkey and the Middle East. The cross-royalty rate has been reduced for both companies. The royalty rates will be further adjusted until Biogen Idec's increased costs are reimbursed.

Go back to previous page